Effect of Intranasal Vasopressin on Cooperative Behavior in Schizophrenia

• Status: Completed
• Trial end date: 2018-11-30
• Target enrollment: 0
• Participant gender: All

Summary

The study investigates the effect of 40IU of intranasal vasopressin on cooperative behavior in patients with schizophrenia

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Mental Health and Neuro Sciences, India
• Treatments: Arginine Vasopressin; Vasopressins

Criteria

Inclusion Criteria:

• Age 18-45 years

• Diagnosed as Schizophrenia or Schizophreniform disorder as per DSM IV TR

• At least 7 years of formal education

• MOCA score >24

Exclusion Criteria:

• Diagnoses of SIADH, Diabetes Insipidus

• Substance dependence in the past 12 months, excluding nicotine dependence

• Current comorbid axis 1 psychiatric disorder

• Hypersensitivity or previous allergy to Vasopressin

• Serious medical or neurological illness which may interfere with assessment and administration of vasopressin

• Hypertension

• Impaired renal functions based on serum creatinine above 1.5

• Electrolyte imbalance

• Receiving ECT or has received ECT in the past 8 weeks

• Clinical history of mental retardation

• Pregnancy • Lactation

• Risk of harm to self or others

• Any significant nasal pathology which may hinder the intranasal absorption of the drug

• Hearing or visual impairment that significantly affects the comprehension and execution of the study